flutamide has been researched along with Metastase in 48 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer." | 7.67 | Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988) |
| "In a recent intergroup study under the auspices of the National Cancer Institute, 603 eligible patients with newly diagnosed disseminated adenocarcinoma of the prostate were prospectively randomized in a double-blinded clinical trial to receive either a gonadotropin-releasing hormone analogue (leuprolide) and a nonsteroidal antiandrogen (flutamide) or leuprolide and placebo." | 5.07 | The use of flutamide in hormone-refractory metastatic prostate cancer. ( Benson, RC; Blumenstein, BA; Crawford, ED; Eisenberger, MA; McLeod, DG; Spaulding, JT; Spicer, D, 1993) |
| "The National Cancer Institute of Canada (NCIC) Clinical Trials Group conducted a phase II study of the oral antiandrogen flutamide in 33 patients with metastatic breast cancer." | 3.67 | Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. ( Bramwell, VH; Eisenhauer, EA; Logan, DM; Paterson, AH; Perrault, DJ; Stewart, DJ, 1988) |
| "The number of patients who died of prostate cancer up to this time is insufficient for a definitive analysis of specific survival." | 2.71 | Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. ( Collette, L; de Reijke, TM; Debois, M; Kurth, KH; Mattelaer, J; Pavone-Macaluso, M; Schröder, FH; van Velthoven, RF; Whelan, P, 2004) |
| "A total of 51 patients with metastatic prostate cancer underwent a 6-months period of continuous maximal androgen blockade (MAB) consisting of leuprorelin (3." | 2.71 | Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer? ( Avances, C; Lucas, C; Maubach, L; Mottet, N; Sene, E; Wolff, JM, 2005) |
| "Patients with localized prostate cancer receiving adjuvant chemotherapy had a higher initial objective response rate (95% vs 53%, P = 0." | 2.69 | Adjuvant mitozantrone chemotherapy in advanced prostate cancer. ( Halford, S; Lynch, M; Rigg, A; Roylance, R; Wang, J; Waxman, J, 2000) |
| "To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer." | 2.68 | Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. ( Block, N; Jones, J; Kolvenbag, G; Patterson, AL; Sarosdy, M; Schellhammer, P; Sharifi, R; Soloway, M; Venner, P; Vogelzang, N, 1996) |
| "Of 102 patients with metastatic prostate cancer, 52 were treated with orchidectomy and 50 with CHB; 22 of these received a LHRH analog + Flutamide and 28 orchidectomy + Flutamide." | 2.68 | [Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications]. ( de Torres, JA; Encabo, G; López Pacios, MA; Lorente, JA; Morote, J; Soler Roselló, A; Vallejo, C, 1995) |
| "Flutamide is a novel antiandrogen with fewer side effects." | 2.68 | Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. ( Blum, R; Chang, A; Davis, T; Fisher, H; Hahn, R; Khanna, O; Rosenthal, J; Schinella, R; Trump, D; Witte, R; Yeap, B, 1996) |
| "In patients with > 5 sites of bone metastasis (D2max), the corresponding periods were 9 and 14 months (p = 0." | 2.68 | Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. ( Hubmer, G; Lehnert, M; Pummer, K; Stettner, H, 1997) |
| "Prostate cancer is the most common cancer in American men today." | 2.67 | Controversies in the treatment of metastatic prostate cancer. ( Blumenstein, BA; Crawford, ED; Dorr, FA; Eisenberger, MA; McLeod, DG, 1992) |
| " In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist." | 2.66 | The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. ( Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G, 1988) |
| "The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part." | 2.49 | [Hormonal treatment in prostate cancer]. ( Bastide, C; Bruyère, F; Guy, L; Karsenty, G; Rozet, F, 2013) |
| "For patients with nonmetastatic prostate cancer, castration alone might be adequately practical and efficient." | 1.36 | Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre. ( Chen, N; Chen, XQ; Huang, R; Huang, Y; Li, X; Wei, Q; Xia, J; Yang, YR; Zeng, H; Zhang, P; Zhu, YC, 2010) |
| "Treatment decisions for metastatic prostate cancer require the consideration of factors such as survival, quality of life, costs of care, and toxicities." | 1.30 | Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs. ( Bennett, CL; Matchar, DB; McCrory, DC, 1997) |
| "Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to androgen independence is frequently observed." | 1.30 | Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. ( Akakura, K; Akimoto, S; Furuya, Y; Igarashi, T; Ito, H; Murakami, S; Shimazaki, J, 1998) |
| "Flutamide withdrawal, when combined with the simultaneous administration of aminoglutethimide, is a therapeutically active approach in patients with "hormone-refractory" prostate cancer." | 1.29 | Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. ( Cooper, M; Figg, WD; Headlee, D; Linehan, WM; Myers, CE; Sartor, O; Steinberg, S; Thibault, A; Tompkins, A; Weinberger, M, 1994) |
| "These data show that PSA synthesis by prostate cancer is reduced after androgen deprivation but that the PSA nadir and PSA doubling time following treatment provide important prognostic information." | 1.29 | Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer. ( Braswell, NT; Feliz, TP; Fowler, JE; Pandey, P; Seaver, LE, 1995) |
| "Flutamide has an incremental cost effectiveness more favorable than most accepted therapies." | 1.29 | Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. ( Bennett, CL; Crawford, ED; Hillner, BE; McLeod, DG, 1995) |
| "In men with severely painful bony metastasis, an inexpensive drug used in Paget's disease, etidronate disodium, may be palliative." | 1.27 | Advances in the treatment of metastatic prostatic cancer. ( Elder, JS; Gibbons, RP, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (20.83) | 18.7374 |
| 1990's | 25 (52.08) | 18.2507 |
| 2000's | 8 (16.67) | 29.6817 |
| 2010's | 5 (10.42) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastide, C | 1 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 1 |
| Rozet, F | 1 |
| Strum, SB | 1 |
| Scholz, MC | 1 |
| Robinson, D | 1 |
| Sandblom, G | 1 |
| Johansson, R | 2 |
| Garmo, H | 1 |
| Aus, G | 1 |
| Hedlund, PO | 2 |
| Varenhorst, E | 2 |
| Yee, DS | 1 |
| Lowrance, WT | 1 |
| Eastham, JA | 1 |
| Maschino, AC | 1 |
| Cronin, AM | 1 |
| Rabbani, F | 1 |
| Chen, XQ | 1 |
| Huang, Y | 1 |
| Li, X | 1 |
| Zhang, P | 1 |
| Huang, R | 1 |
| Xia, J | 1 |
| Chen, N | 1 |
| Wei, Q | 1 |
| Zhu, YC | 1 |
| Yang, YR | 1 |
| Zeng, H | 1 |
| Damber, JE | 1 |
| Hagerman, I | 1 |
| Henriksson, P | 1 |
| Iversen, P | 1 |
| Klarskov, P | 1 |
| Mogensen, P | 1 |
| Rasmussen, F | 1 |
| Corrie, P | 1 |
| Mayer, A | 1 |
| Shaw, J | 1 |
| D'Ath, S | 1 |
| Blagden, S | 1 |
| Blesing, C | 1 |
| Price, P | 1 |
| Warner, N | 1 |
| Pollack, A | 1 |
| Grignon, DJ | 1 |
| Heydon, KH | 1 |
| Hammond, EH | 1 |
| Lawton, CA | 1 |
| Mesic, JB | 1 |
| Fu, KK | 1 |
| Porter, AT | 1 |
| Abrams, RA | 1 |
| Shipley, WU | 1 |
| Nabi, G | 1 |
| Seth, A | 1 |
| Dinda, AK | 1 |
| Gupta, NP | 1 |
| Schröder, FH | 1 |
| Whelan, P | 1 |
| de Reijke, TM | 1 |
| Kurth, KH | 1 |
| Pavone-Macaluso, M | 1 |
| Mattelaer, J | 1 |
| van Velthoven, RF | 1 |
| Debois, M | 1 |
| Collette, L | 1 |
| Martín-Lázaro, J | 1 |
| Buján, JG | 1 |
| Arrondo, AP | 1 |
| Lozano, JR | 1 |
| Galindo, EC | 1 |
| Capdevila, EF | 1 |
| Mottet, N | 1 |
| Lucas, C | 1 |
| Sene, E | 1 |
| Avances, C | 1 |
| Maubach, L | 1 |
| Wolff, JM | 1 |
| Isaacs, JT | 1 |
| Weissman, RM | 1 |
| Coffey, DS | 1 |
| Scott, WW | 1 |
| Sartor, O | 1 |
| Cooper, M | 1 |
| Weinberger, M | 1 |
| Headlee, D | 1 |
| Thibault, A | 1 |
| Tompkins, A | 1 |
| Steinberg, S | 1 |
| Figg, WD | 1 |
| Linehan, WM | 1 |
| Myers, CE | 1 |
| Fowler, JE | 2 |
| Pandey, P | 2 |
| Seaver, LE | 2 |
| Feliz, TP | 2 |
| Braswell, NT | 1 |
| Soloway, MS | 2 |
| Sharifi, R | 2 |
| Wajsman, Z | 1 |
| McLeod, D | 1 |
| Wood, DP | 1 |
| Puras-Baez, A | 1 |
| Scher, HI | 1 |
| Kelly, WK | 1 |
| Hillner, BE | 2 |
| McLeod, DG | 3 |
| Crawford, ED | 3 |
| Bennett, CL | 2 |
| Oosterlinck, W | 1 |
| Mast, P | 1 |
| Benson, RC | 1 |
| Eisenberger, MA | 2 |
| Blumenstein, BA | 2 |
| Spicer, D | 1 |
| Spaulding, JT | 1 |
| Schellhammer, P | 1 |
| Block, N | 1 |
| Soloway, M | 1 |
| Venner, P | 1 |
| Patterson, AL | 1 |
| Sarosdy, M | 1 |
| Vogelzang, N | 1 |
| Jones, J | 1 |
| Kolvenbag, G | 1 |
| Morote, J | 1 |
| Vallejo, C | 1 |
| Lorente, JA | 1 |
| Encabo, G | 1 |
| López Pacios, MA | 2 |
| de Torres, JA | 1 |
| Soler Roselló, A | 2 |
| Zalcberg, JR | 1 |
| Raghaven, D | 1 |
| Marshall, V | 1 |
| Thompson, PJ | 1 |
| Chang, A | 1 |
| Yeap, B | 1 |
| Davis, T | 1 |
| Blum, R | 1 |
| Hahn, R | 1 |
| Khanna, O | 1 |
| Fisher, H | 1 |
| Rosenthal, J | 1 |
| Witte, R | 1 |
| Schinella, R | 1 |
| Trump, D | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Small, EJ | 1 |
| Baron, AD | 1 |
| Fippin, L | 1 |
| Apodaca, D | 1 |
| Datta, SN | 1 |
| Thomas, K | 1 |
| Matthews, PN | 1 |
| Pummer, K | 1 |
| Lehnert, M | 1 |
| Stettner, H | 1 |
| Hubmer, G | 1 |
| Losa, M | 1 |
| Grasso, M | 1 |
| Giugni, E | 1 |
| Mortini, P | 1 |
| Acerno, S | 1 |
| Giovanelli, M | 1 |
| Boccon-Gibod, L | 1 |
| Fournier, G | 1 |
| Bottet, P | 1 |
| Marechal, JM | 1 |
| Guiter, J | 1 |
| Rischman, P | 1 |
| Hubert, J | 1 |
| Soret, JY | 1 |
| Mangin, P | 1 |
| Mallo, C | 1 |
| Fraysse, CE | 1 |
| Furuya, Y | 1 |
| Akimoto, S | 1 |
| Akakura, K | 1 |
| Igarashi, T | 1 |
| Murakami, S | 1 |
| Shimazaki, J | 1 |
| Ito, H | 1 |
| Rosendahl, I | 1 |
| Kiebert, GM | 1 |
| Curran, D | 1 |
| Cole, BF | 1 |
| Weeks, JC | 1 |
| Denis, LJ | 1 |
| Hall, RR | 1 |
| Wang, J | 1 |
| Halford, S | 1 |
| Rigg, A | 1 |
| Roylance, R | 1 |
| Lynch, M | 1 |
| Waxman, J | 2 |
| Morote Robles, J | 1 |
| Vila Barja, J | 1 |
| de Torres Mateos, JA | 1 |
| Dorr, FA | 1 |
| Denis, L | 2 |
| Smith, P | 1 |
| Carneiro de Moura, JL | 1 |
| Newling, D | 1 |
| Bono, A | 1 |
| Keuppens, F | 1 |
| Mahler, C | 1 |
| Robinson, M | 1 |
| Sylvester, R | 2 |
| De Pauw, M | 2 |
| Robinson, MR | 1 |
| Newling, DW | 1 |
| Elder, JS | 1 |
| Gibbons, RP | 1 |
| Williams, G | 1 |
| Sandow, J | 1 |
| Hewitt, G | 1 |
| Abel, P | 1 |
| Farah, N | 1 |
| Fleming, J | 1 |
| Cox, J | 1 |
| O'Donoghue, EP | 1 |
| Sikora, K | 1 |
| Senn, E | 1 |
| Müller, J | 1 |
| Alioth, H | 1 |
| Flamm, J | 1 |
| Fischer, M | 1 |
| Perrault, DJ | 1 |
| Logan, DM | 1 |
| Stewart, DJ | 1 |
| Bramwell, VH | 1 |
| Paterson, AH | 1 |
| Eisenhauer, EA | 1 |
| Irwin, RJ | 1 |
| Prout, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for flutamide and Metastase
| Article | Year |
|---|---|
[Hormonal treatment in prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Benzamides; Co | 2013 |
Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
Topics: Androgen Antagonists; Cyproterone Acetate; Flutamide; Humans; Male; Neoplasm Metastasis; Prostatic N | 1994 |
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Comb | 1985 |
25 trials available for flutamide and Metastase
| Article | Year |
|---|---|
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Flutamide; Goserelin; H | 2010 |
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
Topics: Aged; Antineoplastic Agents, Hormonal; Cardiovascular Diseases; Combined Modality Therapy; Estradiol | 2011 |
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemci | 2002 |
Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Combined Modality Therapy; Diploidy; DNA, Neoplasm; F | 2003 |
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Disease Progression; Flutamide; | 2004 |
Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Drug Administration | 2005 |
Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Topics: Aged; Combined Modality Therapy; Flutamide; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged | 1995 |
Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas | 1995 |
The use of flutamide in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Flutamide; Huma | 1993 |
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Ant | 1996 |
[Final results of complete hormone blockade versus monotherapy in prostatic metastatic cancer. PSA implications].
Topics: Actuarial Analysis; Antineoplastic Agents, Hormonal; Flutamide; Gonadotropin-Releasing Hormone; Huma | 1995 |
Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease Progres | 1996 |
Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal | 1996 |
Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease Progression; Flutamide; Humans; Hy | 1997 |
Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; M | 1997 |
Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Carcinoma; Flushing; | 1997 |
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Flutamide; Goserelin; Humans; Male; Neop | 1999 |
Adjuvant mitozantrone chemotherapy in advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chem | 2000 |
[Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer].
Topics: Drug Evaluation; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1992 |
Controversies in the treatment of metastatic prostate cancer.
Topics: Double-Blind Method; Drug Therapy, Combination; Flutamide; Humans; Leuprolide; Male; Neoplasm Metast | 1992 |
Total androgen ablation: European experience. The EORTC GU Group.
Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; | 1991 |
Flutamide for prostate cancer.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Flutamide; Gonad | 1989 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyp | 1988 |
[Complete androgen blockade (orchiectomy + flutamide) versus androgen blockade with cytostasis (orchiectomy + estramustine) in the treatment of virginal advanced prostate cancer].
Topics: Aged; Aged, 80 and over; Anilides; Clinical Trials as Topic; Combined Modality Therapy; Estramustine | 1988 |
20 other studies available for flutamide and Metastase
| Article | Year |
|---|---|
Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
Topics: Androgen Antagonists; Androgens; Anilides; Drug-Related Side Effects and Adverse Reactions; Flutamid | 2016 |
PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Flutamide; Humans; K | 2008 |
Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; China; Combined Modality Ther | 2010 |
Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Flutamide; Follow-Up | 2004 |
Is photopatch testing useful in the investigation of photosensitivity due to flutamide?
Topics: Androgen Antagonists; Dermatitis, Photoallergic; Diagnosis, Differential; Drug Eruptions; Flutamide; | 2004 |
Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors.
Topics: Acid Phosphatase; Adenocarcinoma; Animals; Castration; Diethylstilbestrol; Disease Models, Animal; F | 1980 |
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Flutamid | 1994 |
Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Topics: Actuarial Analysis; Aged; Aged, 80 and over; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastas | 1995 |
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Topics: Aged; Combined Modality Therapy; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate | 1993 |
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
Topics: Aged; Cost-Benefit Analysis; Flutamide; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pros | 1995 |
Estimating the cost-effectiveness of flutamide in metastatic cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cost-Benefit Analysis; Flutamide; Human | 1996 |
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Costs and Cost Analysis; Flutamide; Humans; Male; Midd | 1997 |
Metastatic prostatic adenocarcinoma presenting as a pituitary mass: shrinkage of the lesion and clinical improvement with medical treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Diagno | 1997 |
Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Androgens; Blood Chemical Analysis; Bone Neoplasms; C | 1998 |
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neopl | 1990 |
Advances in the treatment of metastatic prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Flutamide; Gonadotrop | 1985 |
Combined treatment with flutamide and surgical or medical (LHRH agonist) castration in metastatic prostatic cancer.
Topics: Anilides; Combined Modality Therapy; Cyproterone; Flutamide; Gonadotropin-Releasing Hormone; Humans; | 1986 |
Treatment of prostatic cancer. Newer forms of androgen deprivation.
Topics: Androgen Antagonists; Cyproterone; Cyproterone Acetate; Flutamide; Humans; Male; Megestrol; Megestro | 1986 |
Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study.
Topics: Anilides; Breast Neoplasms; Canada; Drug Evaluation; Flutamide; Follow-Up Studies; Humans; Neoplasm | 1988 |
A new antiprostatic agent for treatment of prostatic carcinoma.
Topics: Adenocarcinoma; Anilides; Flutamide; Gynecomastia; Humans; Male; Neoplasm Metastasis; Prostatic Neop | 1973 |